MEBIAS, an emerging leader in the field of pathway-selective G-protein coupled receptor (GPCR) drug discovery, was founded in January 2016 by 3 highly experienced drug discovery scientists, formerly of Johnson & Johnson and Merck.  Recently, many pharmaceutical firms have struggled with their internal drug pipelines and are increasingly relying on external collaborations. MEBIAS was founded to establish an alternative discovery model, offering a validated, rapid, and highly efficient drug discovery platform.